Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, according to a new report by the Institute of Medicine (IOM). Still, studies involving children continue to be limited, especially in certain areas such as medication use in newborns and long-term safety and effectiveness in children.